

Filed: November 13, 2014

Filed on behalf of:

**Mylan Pharmaceuticals Inc.**

By: Joseph M. Reisman  
Jay R. Deshmukh

KNOBBE, MARTENS, OLSON & BEAR, LLP  
2040 Main Street, 14th Floor  
Irvine, CA 92614  
Ph.: (949) 760-0404 Fax: (949) 760-9502  
E-mail: BoxMylan@knobbe.com

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

**MYLAN PHARMACEUTICALS INC.,**  
Petitioner

v.

**NOVARTIS AG AND LTS LOHMANN THERAPIE-SYSTEME AG,**  
Patent Owners

---

Case No. TBD  
Patent 6,316,023

---

**PETITION FOR *INTER PARTES* REVIEW OF U.S. PATENT 6,316,023**

## TABLE OF CONTENTS

	Page No.
Exhibit list .....	v
I. MANDATORY NOTICES .....	1
A. Real Party-In-Interest .....	1
B. Related Matters.....	1
C. Lead and Back-Up Counsel.....	3
D. Service Information .....	3
II. GROUNDS FOR STANDING.....	4
III. IDENTIFICATION OF CHALLENGE AND STATEMENT OF THE PRECISE RELIEF REQUESTED.....	4
IV. THRESHOLD REQUIREMENT FOR INTER PARTES REVIEW .....	4
V. STATEMENT OF REASONS FOR THE RELIEF REQUESTED .....	5
A. Level of Ordinary Skill in the Art .....	6
B. Claim Construction.....	7
C. Scope and Content of the Prior Art .....	11
1. Rivastigmine Was Being Developed for the Treatment of Alzheimer’s Disease .....	11
2. Rosin Taught the Use of Antioxidants in Compositions Comprising RA <sub>7</sub> (Racemic Rivastigmine) .....	12
3. Elmalem Taught Adding Antioxidants to a Composition Comprising RA <sub>7</sub> to Prevent Oxidation .....	13
4. Enz Taught Transdermal Rivastigmine Compositions .....	14
5. Ebert Taught a Transdermal Drug Delivery System For Liquid, Oxidizable Drugs .....	15

**TABLE OF CONTENTS**  
*(cont'd)*

	<b>Page No.</b>
6. Sasaki Taught Using the Antioxidant Tocopherol to Promote Storage Stability of the Active Ingredient in Transdermal Compositions .....	17
7. The Handbook of Pharmaceutical Excipients Detailed Common Antioxidants Used in Approved Pharmaceutical Compositions .....	18
8. Kissel Disclosed a Transdermal Drug Delivery System With a Release Liner .....	20
D. The Challenged Claims are Unpatentable as Obvious Over the Prior Art.....	20
1. There was Motivation to Select Rivastigmine and Modify Existing Rivastigmine Treatments .....	21
2. Ground 1: Independent Claims 1 and 7 are Obvious Over Enz and the Handbook, Optionally in View of Rosin and/or Elmalem and/or Ebert.....	22
(1) No Secondary Considerations Support Non-Obviousness .....	31
3. Ground 2: Dependent Claim 2 is Unpatentable as Obvious Over Enz and the Handbook and/or Rosin and/or Ebert.....	34
4. Ground 3: Dependent Claims 4 and 5 are Unpatentable As Obvious Over Enz and the Handbook and/or Ebert.....	36
5. Ground 4: Dependent Claim 8 is Unpatentable As Obvious Over Enz, the Handbook, and Ebert or Kissel .....	38
6. Ground 5: Claims 1, 2, 4, 5, and 7 Are Unpatentable As Obvious over Enz and Sasaki .....	39
7. Ground 6: Dependent Claim 8 is Unpatentable As Obvious Over Enz, Sasaki, and Ebert or Kissel .....	46
VI. CONCLUSION.....	48

## TABLE OF AUTHORITIES

	Page No(s).
<i>Asyst Techs., Inc. v. Emtrak, Inc.</i> , 544 F.3d 1310 (Fed. Cir. 2008) .....	33
<i>In re Boecsh</i> , 617 F.2d 272 (CCPA 1980).....	38
<i>In re Geisler</i> , 116 F.3d 1465 (Fed. Cir. 1997) .....	30
<i>In re Kao</i> , 639 F.3d 1057 (Fed. Cir. 2011) .....	33
<i>KSR Int’l Co. v. Teleflex Inc.</i> , 550 U.S. 398 (2007).....	33, 34
<i>MeadWestVaco Corp. v. Rexam Beauty &amp; Closures, Inc.</i> , 731 F.3d 1258 (Fed. Cir. 2013) .....	31
<i>Merck &amp; Co. v. Teva Pharms. USA, Inc.</i> , 395 F.3d 1364 (Fed. Cir. 2005) .....	32, 33
<i>In re Peterson</i> , 315 F.3d 1325 (Fed. Cir. 2003) .....	<i>passim</i>
<i>Pfizer, Inc. v. Apotex, Inc.</i> , 480 F.3d 1348 (Fed. Cir. 2007) .....	31

## OTHER AUTHORITIES

35 U.S.C. § 102.....	<i>passim</i>
35 U.S.C. § 103 .....	4
35 U.S.C. § 311 .....	1
35 U.S.C. § 312.....	1
35 U.S.C. § 313.....	1
35 U.S.C. § 314.....	1, 4

**TABLE OF AUTHORITIES**  
*(cont'd)*

**Page No(s).**

35 U.S.C. § 315.....	1
35 U.S.C. § 316.....	1
35 U.S.C. § 317.....	1
35 U.S.C. § 318.....	1
35 U.S.C. § 319.....	1
37 C.F.R. § 42.....	1, 3
37 C.F.R. § 42.10.....	1
37 C.F.R. § 42.15.....	1
37 C.F.R. § 42.100 <i>et seq.</i> .....	1
37 C.F.R. § 42.104.....	4

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.